4/16/2021  9:59:40 PM Chg. +10.88 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
151.59USD +7.73% 213,403
Turnover: 31.56 mill.
-Bid Size: - -Ask Size: - -USD - -

Business description

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
 

Management board & Supervisory board

CEO
Ugur Sahin
Management board
Özlem Türeci, Ryan Richardson, Sean Marett, Sierk Poetting
Supervisory board
Helmut Jeggle, Michael Motschmann, Prof. Christoph Huber, Ulrich Wandschneider
 

Company data

Name: BioNTech SE
Address: An der Goldgrube 12,DE-55131 Mainz
Phone: +49-6131-9084-0
Fax: +49-6131-9084-390
E-mail: info@biontech.de
Internet: https://biontech.de/de
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: -
IPO date: -

Investor relations

Name: Dr. Sylke Maas
IR phone: -
IR Fax: -
IR e-mail: Investors@biontech.de

Company calendar

CW 20 | 5/10/2021 Interim Report 1st Quarter/3 Months
CW 26 | 6/22/2021 General Shareholder Meeting
CW 33 | 8/9/2021 Interim Report 2nd Quarter/6 Months
CW 46 | 11/9/2021 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

AT Impf GmbH
 
50.33%
Freefloat
 
19.70%
Medine GmbH
 
18.38%
MIG Verwaltungs AG
 
5.98%
FMR LLC
 
5.61%